Literature DB >> 23826456

Acute mono-megakaryoblastic leukemia associated with extreme thrombocytosis and complex karyotype abnormalities.

Rong Hu1, Jia Li, Yanping Hu, Jihong Zhang, Miao Miao, Ke Zhu, Aijun Liao, Wei Yang, Zhuogang Liu.   

Abstract

Patient: Female, 55 Final Diagnosis: Acute leukemia Symptoms: Thrombocytosis Medication: Idarubicin HCl (Zavedos), Pfizer Clinical Procedure: - Specialty: Hematology. Adverse effect of drug therapy.
BACKGROUND: Thrombocytosis is usually seen in myeloproliferative disorders (MPD) and seldom in acute myeloid leukemias (AML). In acute megakaryoblastic leukemia, platelet counts might exceed 1000×109/L in approximately 30% of patients, while others are frequently presented by cytopenias. To our best knowledge there is no report in the literature on acute mono-megakaryoblastic leukemia, especially with extreme thrombocytosis and complex karyotype abnormalities. CASE REPORT: We present the case of a 55-year-old woman with acute mono-megakaryoblastic leukemia with extreme thrombocytosis (greater than 2000×109/L) and complex karyotype abnormalities. The patient was first treated with anti-aggregate therapy and later the patient was put on a regimen consisting of idarubicin 10 mg/m2 daily for 3 days and 200 mg Cytosar daily for 7 days. However, a severe pancytopenia occurred at the first day after chemotherapy and the patient died from intracranial hemorrhage.
CONCLUSIONS: Extreme thrombocytosis and complex karyotype abnormalities in acute mono-megakaryoblastic leukemia are associated with poor outcome.

Entities:  

Keywords:  acute leukemia; karyotype abnormalities; thrombocytosis

Year:  2013        PMID: 23826456      PMCID: PMC3700456          DOI: 10.12659/AJCR.889043

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


Background

Thrombocytosis is usually seen in myeloproliferative disorders (MPD) and seldom in acute myeloid leukemias (AML). In acute megakaryoblastic leukemia, platelet counts might exceed 1000×109/L in approximately 30% of the patients, while others frequently presented by cytopenias [1]. Acute megakaryoblastic leukemia is a rare disease, accounting for only 0.5–1.2% of newly diagnosed adult acute myeloid leukemias (AML) with poor outcomes [2,3]. To our best knowledge, this is the first report on acute mono-megakaryoblastic leukemia, especially with extreme thrombocytosis and complex karyotype abnormalities.

Case Report

We report a rare case of acute mono-megakaryoblastic leukemia with extreme thrombocytosis (more than 2000×109/L) and complex karyotype abnormalities. A 55-year-old woman was admitted to the Hematology Department with dyspepsia. There was no history of previous exposure to cytotoxic agents, long-time radiotherapy, or occupational toxins. There was multiple lymphadenopathy and no splenomegaly. A complete blood count showed extreme thrombocytosis (up to 2646×109/L), with normal hemoglobin (130 g/L), and normal white blood cells (WBC) (9.7×109/L). Examination of peripheral blood film revealed blasts were about 60%. The bone marrow aspirate was hypercellular. There was immature monoblast cells (Figure 1A) (up to 61.5%), as well immature megakaryoblast cells (Figure 1B) (up to 21.7%).
Figure 1

(A) Bone marrow smear: monoblastic cells. (B) Bone marrow smear: megakaryoblastic cells.

Regarding all cytochemical reactions: myeloperoxidase was slightly positive, a-Naphthyl acetate esterase was partly slightly positive (the further inhibition test by NaF was positive), and the PAS reaction was partly positive in the blast cells. The immunophenotype was determined on lysed bone marrow sample by flow cytometry (Figure 2). The results were: R6 abnormal myeloblast cells accounting for 32.67%, expressing HLA-DR, CD45, CD33, CD56, and CD13; partial cells expressing CD117, CD34, CD9, CD2, CD16, CD64, CD14, and CD61; R3 may be megakaryocytes accounting for 42.47% expressing CD45, CD9, and CD61; and partial cells expressing CD34,CD41a and few cells expressing CD2.
Figure 2

Flow cytometry profile of bone marrow blast cells.

Cytogenetics was performed using bone marrow specimens, which were cultured according to standard methods. Twenty-four metaphases were analyzed to detect clonal abnormalities following ISCN guidelines (1995). The bone marrow karyotype revealed (Figure 3): 41∼45, xx, -2, add(3)(p24), del(3)(q24), -5, -6, i(7)(q10), -8, -12 ,-14 ,-17 ,-21, add(21)(q22), del(22)(q12) [CP12]/46, xx[3]. The presence of BCR-ABL (p210BCR-ABL and p190BCR-ABL), JAK2-V617F and FIP1-PDGFRα mRNAs were studied by reverse transcription polymerase chain reaction (RTPCR) bone marrow cells. The results were negative.
Figure 3

Karyotype analysis.

The patient was first treated with anti-aggregate therapy because of the extreme thrombocytosis. Later on the patient was put on a regimen consisting of idarubicin 10 mg/m2 daily for 3 days and 200 mg Cytosar daily for 7 days. However, a severe pancytopenia (platelet: 34×109/L; hemoglobin; 83 g/L: white blood cell: 0.1×109/L) occurred at the first day after chemotherapy and the patient died from intracranial hemorrhage.

Discussion

In the WHO classification, acute megakaryoblastic leukemia is defined by more than 20% of blasts of megakaryocyte lineage in the bone marrow aspirate as determined by morphology and immuno flow cytometry. In this case, the bone marrow aspirate showed more than 20% of monoblast cells and megakaryoblast cells, respectively. Further immunophenotyping confirmed the diagnosis. The short duration of symptoms, the normal blood counts 1 month before admission, and the absence of BCR-ABL and JAK2-V617F rearrangement suggest that this patient had de novo AML. The chromosome abnormalities so far described in adult acute megakaryoblastic leukemia appear to be associated with trisomy 8, -7/del(7q), -5/ del(5q), aberrations of 3q21q26, i(12)(p10), and other structural changes [4]. The reports of AML with thrombosis and karyotype abnormalities are rare. Balatzenko et al. reported a patient with acute megakaryoblastic leukemia with extreme thrombocytosis and p190(bcr/abl) rearrangement [5]. Chang et al. reported a patient with acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation [6]. Lim et al. reported a patient with t(1;3)(p36;q21) and extreme thrombocytosis [7]. In this case, the patient showed complex karyotype abnormalities, which was consistent with this patient’s poor outcome.

Conclusions

Acute mono-megakaryoblastic leukemia associated with extreme thrombocytosis and complex karyotype abnormalities is rare. Extreme thrombocytosis and complex karyotype abnormalities in acute mono-megakaryoblastic leukemia are associated with poor outcome.
  7 in total

Review 1.  Uncommon subtypes of acute nonlymphocytic leukemia: clinical features and management of FAB M5, M6 and M7.

Authors:  B A Peterson; E G Levine
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

Review 2.  Acute myeloid leukemia associated with t(1;3)(p36;q21) and extreme thrombocytosis: a clinical study with literature review.

Authors:  Gayoung Lim; Min Jin Kim; Seung Hwan Oh; Sun Young Cho; Hee Joo Lee; Jin-Tae Suh; Juhie Lee; Woo-In Lee; Kyung Sam Cho; Tae Sung Park
Journal:  Cancer Genet Cytogenet       Date:  2010-12

3.  Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.

Authors:  M S Tallman; D Neuberg; J M Bennett; C J Francois; E Paietta; P H Wiernik; G Dewald; P A Cassileth; M M Oken; J M Rowe
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

4.  Acute megakaryoblastic leukemia: experience of GIMEMA trials.

Authors:  L Pagano; A Pulsoni; M Vignetti; L Mele; L Fianchi; M C Petti; S Mirto; P Falcucci; P Fazi; G Broccia; G Specchia; F Di Raimondo; L Pacilli; P Leoni; S Ladogana; E Gallo; A Venditti; G Avanzi; A Camera; V Liso; G Leone; F Mandelli
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

5.  Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH).

Authors:  Nicole Dastugue; Marina Lafage-Pochitaloff; Marie-Pierre Pagès; Isabelle Radford; Christian Bastard; Pascaline Talmant; Marie Joelle Mozziconacci; Claude Léonard; Christelle Bilhou-Nabéra; Christine Cabrol; Anne-Marie Capodano; Pascale Cornillet-Lefebvre; Michel Lessard; Francine Mugneret; Christine Pérot; Sylvie Taviaux; Odile Fenneteaux; Eliane Duchayne; Roland Berger
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

6.  Acute megakaryoblastic leukaemia with extreme thrombocytosis and p190(bcr/abl)rearrangement.

Authors:  G Balatzenko; M Guenova; J Zechev; S Toshkov
Journal:  Ann Hematol       Date:  2003-11-13       Impact factor: 3.673

Review 7.  Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature.

Authors:  Victor T Chang; Hana Aviv; Leslie M Howard; Frank Padberg
Journal:  Am J Hematol       Date:  2003-01       Impact factor: 10.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.